<p>Cullinan Therapeutics（纳斯达克股票代码：CGEM - 获取免费报告）在周五向投资者发布的研究报告中，Wedbush 将其目标价格从 36.00 美元上调至 37.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “跑赢大盘”。Wedbush 的价格目标表明，该股票相较于之前的收盘价有 149.61% 的潜在上涨空间。</p>
<p>获取 <strong>Cullinan Therapeutics</strong> 的提醒：</p>
<p>其他几位研究分析师也最近对 CGEM 发布了报告。HC Wainwright 在 4 月 28 日的研究报告中将 Cullinan Therapeutics 的目标价格从 27.00 美元上调至 30.00 美元，并给予该公司 “买入” 评级。Guggenheim 在 2 月 2 日的研究报告中开始覆盖 Cullinan Therapeutics。他们对该股票给予了 “买入” 评级和 30.00 美元的价格目标。Weiss Ratings 在 4 月 10 日的研究报告中重新发布了对 Cullinan Therapeutics 的 “卖出（d-）” 评级。Zacks Research 在 2 月 19 日的研究报告中将 Cullinan Therapeutics 的评级从 “强力买入” 下调至 “持有”。最后，摩根士丹利在 1 月 8 日的研究报告中重新发布了 “增持” 评级，并对 Cullinan Therapeutics 的股票设定了 30.00 美元的价格目标。八位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Cullinan Therapeutics 目前的平均评级为 “适度买入”，共识目标价格为 30.00 美元。</p>
<p><strong>获取我们关于 Cullinan Therapeutics 的最新研究报告</strong></p>
<h2>Cullinan Therapeutics 股票上涨 0.7%</h2>
<p>纳斯达克：CGEM 的股票在周五开盘价为 14.82 美元。该股票的市值为 9.1087 亿美元，市盈率为-4.42，贝塔值为-0.09。Cullinan Therapeutics 的 12 个月低点为 5.68 美元，12 个月高点为 16.74 美元。该公司的 50 日移动平均线为 14.27 美元，200 日移动平均线为 11.84 美元。</p>
<p>Cullinan Therapeutics（纳斯达克：CGEM - 获取免费报告）最后一次公布财报是在 5 月 7 日。该公司报告的每股收益（EPS）为-0.75 美元，超出市场共识预期的-0.84 美元，超出幅度为 0.09 美元。整体来看，股票研究分析师预计 Cullinan Therapeutics 在当前年度的每股收益将为-3.06 美元。</p>
<h2>内部人士下注</h2>
<p>在其他 Cullinan Therapeutics 的新闻中，内部人士 Jeffrey Alan Jones 在 2 月 20 日的交易中出售了 4,982 股该公司的股票。该股票以平均价格 13.62 美元出售，总价值为 67,854.84 美元。交易后，内部人士持有该公司 164,550 股股票，价值约为 2,241,171 美元。此次交易使其持股比例减少了 2.94%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接访问。此外，首席财务官 Mary Kay Fenton 在 2 月 20 日的交易中出售了 4,398 股该公司的股票。该股票以平均价格 13.62 美元出售，总价值为 59,900.76 美元。交易后，首席财务官直接持有该公司 126,380 股股票，价值为 1,721,295.60 美元。这代表其持股比例减少了 3.36%。该销售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士已出售 86,492 股公司股票，价值为 1,230,319 美元。当前 7.16% 的股票由内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近对该公司的持仓进行了调整。Blue Owl Capital Holdings LP 在第三季度将其在 Cullinan Therapeutics 的持仓提高了 5.2%。Blue Owl Capital Holdings LP 目前拥有 2,510,972 股该公司的股票，价值为 14,890,000 美元，此前在上个季度购买了额外的 125,000 股。AXQ Capital LP 在第三季度购买了 Cullinan Therapeutics 的新头寸，价值为 194,000 美元。Tema Etfs LLC 在第四季度购买了 Cullinan Therapeutics 的新头寸，价值为 383,000 美元。Tudor Investment Corp ET AL 在第三季度将其在 Cullinan Therapeutics 的持仓提高了 30.9%。Tudor Investment Corp ET AL 目前拥有 28,988 股该公司的股票，价值为 172,000 美元，此前在上个季度购买了额外的 6,850 股。最后，SG Americas Securities LLC 在第四季度将其在 Cullinan Therapeutics 的持仓提高了 49.4%。SG Americas Securities LLC 目前拥有 15,631 股该公司的股票，价值为 162,000 美元，此前在上个季度购买了额外的 5,165 股。对冲基金和其他机构投资者目前持有该公司 86.31% 的股票。</p>
<h2>Cullinan Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Cullinan Therapeutics, Inc 是一家生物制药公司，专注于为美国癌症患者开发肿瘤治疗药物。该公司的主导项目包括 CLN-619，这是一种正在进行 I 期临床试验的单克隆抗体，用于治疗实体肿瘤。其开发组合还包括 CLN-049，这是一种人源化双特异性抗体，正在进行 I 期临床试验，用于治疗急性髓性白血病或骨髓增生异常综合症；CLN-418，这是一种人源化双特异性免疫激活剂，正在进行 I 期临床试验，用于治疗多种实体肿瘤；以及 Zipalertinib，这是一种可生物利用的小分子，用于治疗非小细胞肺癌患者。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过 Cullinan Therapeutics</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dFTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dFTQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Cullinan Therapeutics 吗？</h2>
<p>在你考虑 Cullinan Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Cullinan Therapeutics 并不在名单上。</p>
<p>虽然 Cullinan Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

CGEM

<p>Wedbush 将 Cullinan Therapeutics (NASDAQ:CGEM) 的目标股价从 36.00 美元上调至 37.00 美元，维持 “跑赢大盘” 的评级。这个新目标暗示该股票相较于之前的收盘价有 149.61% 的潜在上涨空间。其他分析师也调整了他们的评级，HC Wainwright 设定了 30.00 美元的目标，而 Guggenheim 则以买入评级开始覆盖。目前，该股票的平均评级为 “适度买入”，共识目标价为 30.00 美元。Cullinan Therapeutics 的股票开盘价为 14.82 美元，市值为 9.1087 亿美元</p>

<p>Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) had its target price increased by Wedbush from $36.00 to $37.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an &#34;outperform&#34; rating on the stock. Wedbush's price objective indicates a potential upside of 149.61% from the stock's previous close.</p>
<div class="lb-trans"><p>Cullinan Therapeutics（纳斯达克股票代码：CGEM - 获取免费报告）在周五向投资者发布的研究报告中，Wedbush 将其目标价格从 36.00 美元上调至 37.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “跑赢大盘”。Wedbush 的价格目标表明，该股票相较于之前的收盘价有 149.61% 的潜在上涨空间。</p>
</div><p>Get <strong>Cullinan Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Cullinan Therapeutics</strong> 的提醒：</p>
</div><p>Several other research analysts have also recently issued reports on CGEM. HC Wainwright lifted their target price on Cullinan Therapeutics from $27.00 to $30.00 and gave the company a &#34;buy&#34; rating in a research report on Tuesday, April 28th. Guggenheim assumed coverage on Cullinan Therapeutics in a research report on Monday, February 2nd. They issued a &#34;buy&#34; rating and a $30.00 price objective on the stock. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Cullinan Therapeutics in a research report on Friday, April 10th. Zacks Research cut Cullinan Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, February 19th. Finally, Morgan Stanley reissued an &#34;overweight&#34; rating and issued a $30.00 price objective on shares of Cullinan Therapeutics in a research report on Thursday, January 8th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Cullinan Therapeutics presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $30.00.</p>
<div class="lb-trans"><p>其他几位研究分析师也最近对 CGEM 发布了报告。HC Wainwright 在 4 月 28 日的研究报告中将 Cullinan Therapeutics 的目标价格从 27.00 美元上调至 30.00 美元，并给予该公司 “买入” 评级。Guggenheim 在 2 月 2 日的研究报告中开始覆盖 Cullinan Therapeutics。他们对该股票给予了 “买入” 评级和 30.00 美元的价格目标。Weiss Ratings 在 4 月 10 日的研究报告中重新发布了对 Cullinan Therapeutics 的 “卖出（d-）” 评级。Zacks Research 在 2 月 19 日的研究报告中将 Cullinan Therapeutics 的评级从 “强力买入” 下调至 “持有”。最后，摩根士丹利在 1 月 8 日的研究报告中重新发布了 “增持” 评级，并对 Cullinan Therapeutics 的股票设定了 30.00 美元的价格目标。八位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Cullinan Therapeutics 目前的平均评级为 “适度买入”，共识目标价格为 30.00 美元。</p>
</div><p><strong>Get Our Latest Research Report on Cullinan Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Cullinan Therapeutics 的最新研究报告</strong></p>
</div><h2>Cullinan Therapeutics Stock Up 0.7%</h2>
<div class="lb-trans"><h2>Cullinan Therapeutics 股票上涨 0.7%</h2>
</div><p>Shares of NASDAQ:CGEM opened at $14.82 on Friday. The stock has a market cap of $910.87 million, a price-to-earnings ratio of -4.42 and a beta of -0.09. Cullinan Therapeutics has a 12-month low of $5.68 and a 12-month high of $16.74. The business's 50 day moving average is $14.27 and its 200 day moving average is $11.84.</p>
<div class="lb-trans"><p>纳斯达克：CGEM 的股票在周五开盘价为 14.82 美元。该股票的市值为 9.1087 亿美元，市盈率为-4.42，贝塔值为-0.09。Cullinan Therapeutics 的 12 个月低点为 5.68 美元，12 个月高点为 16.74 美元。该公司的 50 日移动平均线为 14.27 美元，200 日移动平均线为 11.84 美元。</p>
</div><p>Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.09. As a group, equities research analysts expect that Cullinan Therapeutics will post -3.06 earnings per share for the current year.</p>
<div class="lb-trans"><p>Cullinan Therapeutics（纳斯达克：CGEM - 获取免费报告）最后一次公布财报是在 5 月 7 日。该公司报告的每股收益（EPS）为-0.75 美元，超出市场共识预期的-0.84 美元，超出幅度为 0.09 美元。整体来看，股票研究分析师预计 Cullinan Therapeutics 在当前年度的每股收益将为-3.06 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Cullinan Therapeutics news, insider Jeffrey Alan Jones sold 4,982 shares of the business's stock in a transaction on Friday, February 20th. The stock was sold at an average price of $13.62, for a total value of $67,854.84. Following the transaction, the insider owned 164,550 shares of the company's stock, valued at approximately $2,241,171. The trade was a 2.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, CFO Mary Kay Fenton sold 4,398 shares of the company's stock in a transaction on Friday, February 20th. The shares were sold at an average price of $13.62, for a total value of $59,900.76. Following the transaction, the chief financial officer directly owned 126,380 shares in the company, valued at $1,721,295.60. This represents a 3.36% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 86,492 shares of company stock valued at $1,230,319. 7.16% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他 Cullinan Therapeutics 的新闻中，内部人士 Jeffrey Alan Jones 在 2 月 20 日的交易中出售了 4,982 股该公司的股票。该股票以平均价格 13.62 美元出售，总价值为 67,854.84 美元。交易后，内部人士持有该公司 164,550 股股票，价值约为 2,241,171 美元。此次交易使其持股比例减少了 2.94%。该交易已在向证券交易委员会提交的文件中披露，文件可通过此链接访问。此外，首席财务官 Mary Kay Fenton 在 2 月 20 日的交易中出售了 4,398 股该公司的股票。该股票以平均价格 13.62 美元出售，总价值为 59,900.76 美元。交易后，首席财务官直接持有该公司 126,380 股股票，价值为 1,721,295.60 美元。这代表其持股比例减少了 3.36%。该销售的披露信息可在 SEC 文件中找到。在过去 90 天内，内部人士已出售 86,492 股公司股票，价值为 1,230,319 美元。当前 7.16% 的股票由内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently made changes to their positions in the company. Blue Owl Capital Holdings LP lifted its position in shares of Cullinan Therapeutics by 5.2% during the 3rd quarter. Blue Owl Capital Holdings LP now owns 2,510,972 shares of the company's stock valued at $14,890,000 after buying an additional 125,000 shares during the last quarter. AXQ Capital LP purchased a new position in shares of Cullinan Therapeutics during the 3rd quarter valued at $194,000. Tema Etfs LLC purchased a new position in shares of Cullinan Therapeutics during the 4th quarter valued at $383,000. Tudor Investment Corp ET AL lifted its position in shares of Cullinan Therapeutics by 30.9% during the 3rd quarter. Tudor Investment Corp ET AL now owns 28,988 shares of the company's stock valued at $172,000 after buying an additional 6,850 shares during the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of Cullinan Therapeutics by 49.4% during the 4th quarter. SG Americas Securities LLC now owns 15,631 shares of the company's stock valued at $162,000 after buying an additional 5,165 shares during the last quarter. Hedge funds and other institutional investors own 86.31% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近对该公司的持仓进行了调整。Blue Owl Capital Holdings LP 在第三季度将其在 Cullinan Therapeutics 的持仓提高了 5.2%。Blue Owl Capital Holdings LP 目前拥有 2,510,972 股该公司的股票，价值为 14,890,000 美元，此前在上个季度购买了额外的 125,000 股。AXQ Capital LP 在第三季度购买了 Cullinan Therapeutics 的新头寸，价值为 194,000 美元。Tema Etfs LLC 在第四季度购买了 Cullinan Therapeutics 的新头寸，价值为 383,000 美元。Tudor Investment Corp ET AL 在第三季度将其在 Cullinan Therapeutics 的持仓提高了 30.9%。Tudor Investment Corp ET AL 目前拥有 28,988 股该公司的股票，价值为 172,000 美元，此前在上个季度购买了额外的 6,850 股。最后，SG Americas Securities LLC 在第四季度将其在 Cullinan Therapeutics 的持仓提高了 49.4%。SG Americas Securities LLC 目前拥有 15,631 股该公司的股票，价值为 162,000 美元，此前在上个季度购买了额外的 5,165 股。对冲基金和其他机构投资者目前持有该公司 86.31% 的股票。</p>
</div><h2>Cullinan Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Cullinan Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.</p>
<div class="lb-trans"><p>Cullinan Therapeutics, Inc 是一家生物制药公司，专注于为美国癌症患者开发肿瘤治疗药物。该公司的主导项目包括 CLN-619，这是一种正在进行 I 期临床试验的单克隆抗体，用于治疗实体肿瘤。其开发组合还包括 CLN-049，这是一种人源化双特异性抗体，正在进行 I 期临床试验，用于治疗急性髓性白血病或骨髓增生异常综合症；CLN-418，这是一种人源化双特异性免疫激活剂，正在进行 I 期临床试验，用于治疗多种实体肿瘤；以及 Zipalertinib，这是一种可生物利用的小分子，用于治疗非小细胞肺癌患者。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Cullinan Therapeutics</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Cullinan Therapeutics</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0dFTQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=CGEM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cullinan Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Cullinan Therapeutics 吗？</h2>
</div><p>Before you consider Cullinan Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Cullinan Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Cullinan Therapeutics 并不在名单上。</p>
</div><p>While Cullinan Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cullinan Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $37.00

Market Beat

Cullinan Therapeutics

摩根士丹利

Blue Owl Capital

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Blue Owl Capital III

Blue Owl Tech Finance

Cullinan Therapeutics（纳斯达克代码：CGEM）的目标股价被上调至 37.00 美元